Menu

Reports

Generics Blue Cap V13C15

India’s pharma moving from generics to niche drugs

Home/Reports | Posted 13/09/2013

Indian pharmaceutical companies will increasingly move away from the overcrowded and competitive area of generics and invest more R & D spending in niche drugs, according to a new report.

ANDA Approval V13F21

Authorized generics reduce drug prices

Home/Reports | Posted 06/09/2013

In what seems to be a bit of a turnaround for the US Federal Trade Commission (FTC), the agency has released a report which suggests that authorized generics can reduce both retail and wholesale drug prices.

picture 112

Ireland’s drug shortages worsening

Home/Reports | Posted 16/08/2013

Drug shortages in Ireland have increased during the last 12 months, according to a recent survey of pharmacists in the country.

Drug shortages V13C22

How to avoid drug shortages

Home/Reports | Posted 09/08/2013

Despite FDA having made progress in recent years to combat drug shortages, the issue is still a major problem for the agency. This very fact led to the agency requesting public comment on the subject in February 2013. Senior Vice President of Quality at Amgen, Mr Martin Van Trieste, makes some suggestions to ensure that patients continue to gain access to essential medicines [1].

Educate Yourself V13H02

US healthcare professionals need more education on biosimilars

Home/Reports | Posted 02/08/2013

A study of healthcare professionals in North America found a lack of knowledge concerning biosimilars and a need for further education on biosimilars.

Drug shortages V13C22

Patient care threatened by cancer drug shortages

Home/Reports | Posted 05/07/2013

Drug shortages are affecting most US oncologists, impacting on life-saving patient care, according to the findings of the largest study yet to quantify the impact of cancer drug shortages [1]. Of 250 board-certified US oncologists surveyed in late 2012 and early 2013, 83% reported facing a drug shortage in the past six months, and 92% of those said their patients’ treatment had been affected.

Biologicals 2 V12K16

Biosimilar competition in Europe

Home/Reports | Posted 05/07/2013

A study of five European Union (EU) countries has revealed that Germany provides the most favourable environment for uptake of biosimilars.

Harmonize V13F28

International harmonization for biosimilars

Home/Reports | Posted 28/06/2013

What is the possibility of international harmonization for biosimilars? EMA Head of Biologicals Dr Peter Richardson and Amgen Director of Value, Access and Policy Mr Thomas Moore speak to BioCentury about this issue, as well as why the US is still lagging behind Europe in the biosimilars race.

Pharmacovigilance V13F21

Biosimilar monoclonal antibodies and pharmacovigilance in Europe

Home/Reports | Posted 21/06/2013

EMA Head of Biologicals Dr Peter Richardson and Amgen Director of Value, Access and Policy Mr Thomas Moore speak to BioCentury about biosimilar monoclonal antibodies and pharmacovigilance for biosimilars in Europe.

Substitution V13F14

Possibility of substitution of biosimilars in Europe

Home/Reports | Posted 14/06/2013

To date, 14 biosimilars within the product classes of human growth hormone (1), granulocyte colony-stimulating factor (8) and erythropoietin (5) have been approved in Europe [1]. EMA Head of Biologicals Dr Peter Richardson and Amgen Director of Value, Access and Policy Mr Thomas Moore speak to BioCentury about substitution of biosimilars in Europe.

Biologicals 1 V13D05

EMA’s Richardson talks about biosimilars in Europe

Home/Reports | Posted 07/06/2013

Biosimilars have been available in Europe for more than seven years. In the US, however, despite legislation being passed in 2010 to allow for a biosimilars pathway, a biosimilar has yet to be approved [1]. EMA Head of Biologicals Dr Peter Richardson speaks to BioCentury about a new report published by the European Commission (EC) and about biosimilars in Europe in general.

picture09

The best selling biotechnology drugs of 2008: the next biosimilars targets

Home/Reports | Posted 14/10/2009

Last updated: 20 September 2013

According to the report Market-Leading Biotechnology Drugs 2009: Blockbuster Dynamics in an Ailing Economy, sales of the top 10 biotech drugs exceeded US$41.5 billion (Euros 28.6 billion) in 2008.

Biosimilars V13E10

Amgen, Hospira and Sandoz set to dominate US biosimilars market

Home/Reports | Posted 31/05/2013

A new report released by Thomson Reuters on 14 May 2013 identifies Amgen, Hospira and Sandoz as having the greatest potential to dominate the early stages of the biosimilars market in the US.

Intellectual Property V13E17

US places India on IP black list

Home/Reports | Posted 17/05/2013

The US has placed India on a special trade black list of countries that have raised concerns about intellectual property rights.

Biosimilars V13E10

Use of biosimilars in Europe

Home/Reports | Posted 10/05/2013

Uptake of biosimilars in Europe is slowly increasing, according to a new report published by the European Commission’s (EC) Enterprise and Industry Directorate-General.

Consensus Report V13E03

EU publishes consensus report on biosimilars

Home/Reports | Posted 03/05/2013

The European Commission’s (EC’s) Enterprise and Industry Directorate-General has published a new report providing comprehensive information on the concept of biosimilars.

Drug shortages V13C22

More UK patients affected by drug shortages in 2012

Home/Reports | Posted 29/04/2013

The number of UK patients affected by shortages in brand-name medicines has increased during 2012, according to an online survey carried out by pharmacists’ organization Chemist+Druggist (C+D).

Patient MD002316 V13C05

Patients in US turn to generics to save money

Home/Reports | Posted 19/04/2013

According to a new report released on 9 April 2013 by the US Centers for Disease Control and Prevention, adults in the US used several strategies to reduce the costs of their medications, including asking their doctor for a lower-cost (generic) medicine.

Ireland flag V13C29

Huge differences in prescription drug prices in Ireland

Home/Reports | Posted 05/04/2013

A survey carried out by Ireland’s National Consumer Agency (NCA) has found that the price of many commonly prescribed medicines varies widely across Ireland.

Generics Blue Cap V13C15

Fewer generics approved in the US during 2012

Home/Reports | Posted 15/03/2013

FDA approved fewer generics for the US market during 2012 than in 2011, according to a new report from Thomson Reuters.